Cholinesterases are efficient scavengers of organophosphates and are currently being developed as drugs for treatment against poisoning by such compounds. Recombinant ChE bioscavengers have very short circular longevity, a limitation that can be overcome by complex post-translation manipulations or by chemical modification such as polyethylene glycol conjugation. Series of multiple Lys-Ala mutants of human acetylcholinesterase were prepared allowing the generation of homogenous and well defined polyethylene-glycol conjugated AChEs with either one, two, three, four, or five appended polyethylene glycol (PEG) moieties/molecule. The rank order of circulatory longevity of these molecules was dependent on the number of PEG appendages up to a certain threshold: 5 ‫؍‬ 4 > 3 > 2 > 1 > 0. Hypolysine acetylcholinesterases (AChEs) carrying the same number of PEGs, and therefore with identical masses, allowed us to demonstrate that circulatory longevity correlates with the predicted extent of concealment of the AChE surface. Furthermore, circulatory profiles of high number and low number PEG-AChEs differing in their sialic acid contents demonstrate a direct relationship between PEG loading and the effective seclusion of AChE from the hepatic asialoglycoprotein receptor clearance system. Finally, an inverse relationship is found between the extent of PEG loading and the ability of the human acetylcholinesterase to elicit specific anti-HuAChE antibodies. In conclusion, these findings suggest that for the extension of circulatory longevity, protein surface domain concealment exerted by polyethylene glycol attachment is at least as important as its effect on size enlargement and highlights the role of PEG attachment in masking interactions between biomolecules and their cognate receptors.
transmission in cholinergic synapses by rapid hydrolysis of the neurotransmitter acetylcholine. Some organophosphate (OP) compounds, such as the nerve agents sarin and soman, inhibit AChE irreversibly by rapid phosphonylation of the serine residue in the enzyme active site. The high reactivity of cholinesterases (ChEs) toward OP agents led to propose these biomolecules as exogenous scavengers for sequestration of toxic OP agents before they reach their physiological target (Refs. 1-3 and references therein). Because ChEs react on a molar basis with the OP agents, the amounts of ChE required for sequestration of these compounds are high. This requirement encouraged the development of production systems for the generation of recombinant ChEs at large scale (4 -6) . However, pharmacokinetic studies (4, 7) have shown that recombinant ChEs are retained in the circulation of experimental animals for much shorter periods of time than native fetal bovine serum acetylcholinesterase or human serum butyrylcholinesterase (BChE).
Previous studies allowed us to determine that by optimizing sialic acid occupancy, enzyme tetramerization, and glycan loading, bovine and human recombinant AChEs can be converted into circulatory long-lived enzyme forms exhibiting mean residence time values that are similar to those of native serumderived cholinesterases (8 -10) . In addition, we identified a species-dependent amino acid-specific elimination process that operates in determining the circulatory fate of AChEs, overriding the positive contribution of post-translation-related processes (i.e. enzyme assembly and glycan loading) to circulatory retention (11) .
In parallel, we demonstrated that controlled conjugation of polyethylene glycol (PEG) to lysine residues of rHuAChE or rHuBChE can generate bioactive enzymes exhibiting improved pharmacokinetic profiles (12, 13) . Circulatory retention rates of PEGylated AChE in mice (mean residence time ϭ 2100 min) were found to surpass those of native serum-derived enzymes such as the fetal bovine serum AChE (12) . In the rhesus animal model, PEGylated AChE demonstrated an unprecedented circulatory retention time value (MRT ϭ ϳ7 days) (11) , suggesting that AChE PEGylation bestows the enzyme with pharmacological properties suitable for its application as a prophylactic bioagent against OP intoxication. Indeed, PEGylated recombinant AChE was shown to confer high level protection to mice exposed to various OP agents. Most importantly, unlike nonmodified recombinant AChE, the PEGylated version of recombinant AChE provided excellent protection even when administered 24 h before exposure of mice to nerve agents such as O-ethyl-S-(2-isopropylaminoethyl)methylphosphonothiolate (VX) (14) .
Although exhaustive PEGylation of all lysines of the wild type rAChE may result in the generation of uniform PEGylated enzyme, such a chemically modified enzyme product was shown to be devoid of enzymatic activity (12) . However, under a defined set of conditions, four or five PEG molecules on average may be appended to monomeric rHuAChE with minimal effect on the catalytic properties of the enzyme (12, 14) . Such preparations comprise heterogeneous enzyme products differing in amounts of PEG-attached moieties/AChE molecule. We could further determine that circulatory retention of PEGAChEs depends on the average number and size of the PEG subunits attached to the enzyme (12) . However, because of the heterogeneous nature of the differently PEGylated enzyme preparations, we could not determine in a precise manner the contribution of PEG loading levels and PEG locations to circulatory retention of AChE.
Here we report on the generation of an array of uniformly PEGylated recombinant human AChE molecules where each of the homogenous AChE preparations differed one from another in number and location of appended PEG chains at the enzyme surface. This allowed us to reveal some important aspects of site-specific PEGylation with respect to the masking of surfacerelated epitopes involved in different biological interactions between AChE and host-related factors.
EXPERIMENTAL PROCEDURES

Generation of rHuAChE Mutants and Molecular Modeling-
The generation of the C-terminal tail deleted version of rHuAChE, ⌬C-rHuAChE, was described previously (15, 16) . The various lysine-to-alanine mutations were generated using a commercial site-directed mutagenesis kit (QuikChange; Stratagene). Multiple lysine rHuAChE mutants were generated by exchanging relevant fragments between the various single-lysine mutants and verified by DNA sequencing. Visual examination of the molecular structures of rHuAChE and the various hypolysine-mutated AChEs was achieved using the molecular modeling package SYBYL 6.7 running on a SGI Octane work station. The conformation of the enzyme was obtained from the HuAChE x-ray structure (16) (Protein Data bank code 1B41).
Cell Culture Techniques-HEK-293 cell lines stably expressing high levels of ⌬C-rHuAChE and various hypolysine mutant rHuAChEs were generated as described previously (8, 9) . AChEs produced and secreted by these cells are consistently sialylated in a partial manner (ϳ60% sialylation) (8 -10) . The generation of mutant AChEs displaying highly sialylated N-glycans (ϳ90% sialylation) was achieved by transfecting the recombinant sialyltransferase expressor HEK-293ST-2D6 cell line (8) with the vectors coding for various hypolysine AChEs, followed by G418 selection to form stable producer cells.
Enzyme Preparation and Structural Analysis of GlycansPurification of the secreted AChEs from stably transfected HEK-293 cells and HEK-293ST-2D6 was carried out as described (17) . Desialylation of purified AChEs was performed as described previously (18) . Release, recovery, purification, labeling, and analysis by MALDI-TOF of N-glycans were all described before (8) .
Enzyme Activity, Specific Activity, and Thermostability Assays-AChE activities of purified AChE preparations were measured according to Ellman et al. (19) as described previously (8) . The various hypolysine AChE protein products were quantified by ELISA, and the specific activity of each mutant product was calculated by dividing the enzymatic activity to protein quantity. The various hypolysine mutants were examined for thermal stability by incubating the enzymes at 37°C for various periods of time followed by measurement of residual enzymatic activity. The thermal decay curve of each of the mutant AChE forms was profiled, and half-life time values were determined.
Conjugation of Polyethylene Glycol to AChE-Attachment of PEG chains to primary amines in the various rHuAChEs was performed using succinimidyl propionate-activated methoxy PEG (Shearwater Polymers, Inc.) at a ratio of 50:1 [PEG] 0 / [AChE primary amines] 0 as described previously (12) .
Clearance Experiments and Analysis of Pharmacokinetic Profiles in Mice-Male outbred ICR mice (Charles River Laboratories) were maintained at 20 -22°C and relative humidity of 50 Ϯ 10% on a 12-h light-dark cycle, fed with commercial rodent chow (Koffolk, Inc., Tel-Aviv, Israel), and provided with tap water ad libitum. The treatment of animals was in accordance with regulations outlined in the United States Department of Agriculture Animal Welfare Act and the conditions specified in The Guide for Care and Use of Laboratory Animals of the National Institute of Health. All of the pharmacokinetic studies were approved by the local ethical committee on animal experiments.
Clearance experiments (three to six mice/enzyme sample) were carried out essentially as described previously (17) . The mice were injected intravenously with the various rHuAChE preparations (100 units/mouse in 0.2 ml of phosphate-buffered saline). Residual AChE activity in blood samples was measured, and all of the values were corrected for background hydrolytic activity in the blood (using samples withdrawn 1 h before performing the experiment). AChE activity values in samples removed 1 min after injection were assigned a value of 100% and used for calculation of residual activity. The background cholinesterase levels in blood of preadministered mice were less than 2 units/ml.
The clearance patterns of the various enzyme preparations were usually biphasic and fitted to a bi-exponential elimination pharmacokinetic model (C t ϭ Ae Ϫk␣t ϩ Be Ϫk␤t ) as described previously (8, 9) . The pharmacokinetic parameter MRT (which reflects the average length of time the administered molecules are retained in the organism) was independently obtained by analyzing the clearance data according to a noncompartmental pharmacokinetic model using the WinNonlin computer program (20) .
Immunogenicity Tests-For immunogenicity studies, mice (10 mice/group) were administered at monthly intervals with 10 g/mouse of either non-PEGylated or PEGylated HuAChE or hypolysine rHuAChEs. Anti-AChE antibody titers in blood samples removed at various periods of time were determined by direct ELISA (21) .
RESULTS
Effect of Replacements of Lysine Residues by Alanine on the
Structural and Functional Integrity of Human AChE-As a first step toward the generation of human AChE with reduced PEGylation target sites, we determined which of the lysine residues may be replaced without compromising enzymatic performance or structural integrity of the AChE molecule. To this end, we replaced each of the seven lysine residues of the ⌬C-rHuAChE with alanine residues and examined whether the replacements affected the catalytic performance of the mutated enzyme. All of the seven single lysine mutants of ⌬C-rHuAChE displayed similar specific activities (as determined by hydrolytic activity and ELISA), differing from that of the wild type enzyme by no more than a factor of 3 ( Fig. 1) . This finding demonstrated that any of the individual lysine residues may be substituted without significantly altering the enzyme structure or function, and therefore each of these residues can be considered as a candidate for removal when generating multilysine-mutated AChEs.
Generation of Enzymatically Active and Fully PEGylated Human AChE Derivatives Carrying Multiple Lys-Ala Replacements-In the past we demonstrated (12) that appendage of more than four or five PEG chains/human AChE enzyme subunit is accompanied by a reduction in enzymatic activity, and therefore, at least three of the seven AChE lysine residues should be eliminated to allow no more than four free lysine residues for PEG appendage. Accordingly we generated a series of different hypolysinemutated AChEs containing three to seven Lys-Ala mutations, corresponding to AChEs having only zero, one, two, three, or four lysine residues (i.e. between one and five PEG target sites including the N-terminal primary amine). HEK-293 cell clones stably expressing high levels of the corresponding hypolysine AChEs were generated, and production levels of all the various AChE derivatives were found to be within the range of 5-20 units/ 10 6 cells/24 h. The various hypolysine AChEs were quantified by capture ELISA, using polyclonal anti-human AChE antibodies of mouse and rabbit source (21) . In all cases, catalytic activity-to-protein mass ratios (specific activity) were similar, differing from that of the wild type ⌬C-rHuAChE by no more than a factor of 3 ( Fig. 1) . These results indicate that the elimination of multiple lysine residues did not cause any gross alteration in the enzyme architecture. Thermal stability of the various multiple lysine-mutated AChEs was monitored by incubating the enzymes at 37°C and determining residual AChE activity at different time points. In all cases, thermal stability of the mutated AChE forms was in the same range (half-life values: 110 -218 h) and similar to that determined for the wild type enzyme (T1 ⁄ 2 ϭ 230 h) (Fig.  1) . All of the clones expressing the various mutated hypolysine AChE were propagated to a large scale and purified.
The resulting preparations of the seven different purified hypolysine ⌬C-rHuAChEs (Figs. 1 and 2) were subjected to PEGylation under conditions that favor PEG saturation, so that FIGURE 1. Specific activity and thermal stability of wild type (WT) and lysine-to-alanine mutated AChEs. Specific activity is expressed as units of AChE (determined according to Ellman et al. (19) )/microgram of secreted enzyme (determined by ELISA (21)). Thermal stability values are expressed as half-life (hours) of enzymatic activity at 37°C. Framed numbers (top line) designate positions of lysine residues in wild type ⌬C-AChE. The vertical lines represent lysine residues present in each of the enzyme forms. A represents lysineto-alanine substitutions. The black dots represent target sites available for PEG appendage in the multiple lysine-to-alanine substitutions. ND, not determined.
each of the hypolysine AChE forms will display a single uniform product following PEGylation. Indeed, the various AChE forms carrying one to five PEG chains/enzyme subunit ran on SDS gels as discrete well defined single bands with apparent molecular weights in accordance with that expected from complete PEGylation of all the available PEG-target sites (Fig. 2 ). Most importantly, full PEGylation of all the hypolysine AChEs did not affect their catalytic activities, which were indistinguishable from those determined prior to PEGylation (Fig. 1 ). As mentioned above, in the case of wild type AChE containing seven lysine residues (eight potential PEG attachment sites), a considerable loss of enzymatic activity was observed under conditions that favored full PEGylation and appendage to more than five target sites. These findings demonstrate that reduction of lysine PEG target sites can provide a solution for the difficulty in generating homogenous and uniformly PEGylated catalytically active AChE derivatives.
Pharmacokinetic Profiling of Hypolysine Mutant AChEs Differing in the Number of PEG-appended Chains-To determine the effect of PEG number on the circulatory residence of AChE, the elimination profiles in mice was determined for representative hypolysine PEG-AChEs (Fig. 3A) . In general, enzyme forms exhibiting an increase in appended PEG chains were retained in the circulation for longer periods of time. The appendage of a single PEG chain to the alysine AChE (where PEG can be appended to the terminal primary amine of the enzyme only) significantly increased the MRT of the molecule from 42 to 365 min (Fig. 3A , compare bars a and b). Appendage of additional PEG chains was accompanied by a gradual increase in circulatory residence, so that fully PEGylated monolysine, dilysine, and trilysine AChEs (Fig. 3A, bars c, d , and e containing two, three, and four PEGs/enzyme subunit, respectively,) displayed MRT values of 520, 770, and 1860 min, respectively. Appendage of a fifth PEG moiety to AChE (by PEGylation of the tetralysine-AChE) did not contribute significantly to the circulatory residence of the PEGylated enzyme (Fig. 3A , bar f; MRT ϭ 1810 min). The MRT values of the enzyme forms carrying four and five PEG chains was within the range of 1800 -1900 min, comparable with that of the wild type enzyme randomly PEGylated under conditions that favor the appendage of four to five PEG moieties (MRT ϭ ϳ2000 Ϯ 200 min).
The Effect of Low Number PEG-attached Moieties on the Pharmacokinetic Performance of AChE Exhibiting Various Levels of Glycan
Sialylation-Extensive studies exhibited that terminal glycan sialylation of AChE plays an important role in determining the circulatory fate of the enzyme, so that suboptimally sialylated AChE is eliminated rapidly from the circulation via the hepatic asialoglycoprotein removal pathway (8 -10) . Nevertheless, the desialylated, the partially sialylated, and the fully sialylated PEG-AChEs, all containing an average of four to five PEG chains, exhibit similar MRT values of ϳ1900 min (13, 22) , indicating that sufficiently high levels of PEGylation render the enzyme inaccessible to asialoglycoprotein receptors. In the present study, we demonstrate that mutant hypolysine AChEs carrying one, two, or three PEG chains are retained in circulation for lesser periods of time than enzyme forms carrying four to five PEGs/enzyme subunit (see above). Because all of these enzyme forms were produced in HEK-293 cells, which allow only partial sialylation of the enzyme product (9, 18), we examined whether the limited circulatory retention exhibited by the low number PEG-AChEs can be attributed to removal via the asialoglycoprotein receptor system. To this end, we examined the pharmacokinetic behavior of various PEGylated hypolysine AChEs, which differ in their sialic acid contents. The mutants tested include Lys 53 /Lys 470 /Lys 496 / Lys 538 AChE (five available PEG sites) and Lys 470 AChE (two available PEG sites). Partially sialylated forms of these two mutant AChEs were produced in nonmodified HEK-293 cells, which support limited sialylation of the enzyme product (9, 18) (Fig. 4A) . Enzyme versions totally devoid of sialic acid were produced by subjecting these two mutant AChEs, collected from HEK-293 cells, to sialidase treatment, whereas the fully sialylated enzymes were obtained by transfecting the two selected Lys-Ala AChE-expressing vectors into the genetically modified 2D6ST cell line, which is a derivative of HEK-293 engineered to express high levels of ␣-2,6-sialyltransferase (9, 18) . The extent of sialylation of each of these various AChE products was verified and quantified by MALDI-TOF analysis of their N-glycans (see "Experimental Procedures"). As expected (8, 9) , the levels of sialic termini were 0, 60, and over 90% in the desialylated, partially sialylated, and fully sialylated AChEs, respectively (Fig. 4A) . Each of the three differently sialylated versions of the two purified hypolysine mutants were fully PEGylated and then subjected to pharmacokinetic analysis. In the case of Lys 53 /Lys 470 /Lys 496 /Lys 538 AChE, the desialylated, the partially sialylated and the fully sialylated AChE forms exhibited MRT values of 3, 42, and 100 min, respectively (Fig. 4B, inset) , in agreement with previous findings for wild type ⌬C-rHuAChE. Yet following the appendage of five PEG chains, all of the differently sialylated forms were retained in the circulation in a similar manner, exhibiting essentially identical MRT values of ϳ1900 min (Fig. 4B) . In the case of Lys 470 AChE, which contains only two PEGylation target sites, the appendage of PEG chains also resulted in extension of circulatory residence; however, in this case the MRT values of the differently sialylated Lys 470 AChEs clearly depended on their sialic acid contents (Fig. 4C) . Thus following PEGylation desialylated, partially sialylated, and fully sialylated Lys 470 AChEs displayed MRT values of 20, 520, and 650 min, respectively. These findings demonstrate that following appendage of a low number of PEGs to AChE, as in the case of Lys 470 AChE, the level of sialylation does affect the pharmacokinetic performance of the enzyme because the chemically modified product appears to remain, at least to some extent, accessible to the asialoglycoprotein receptor. If indeed, some regions of the molecular surface remain exposed following the appendage of a low number of PEGs, these exposed regions may serve as epitopes for interaction in other biological processes such as immunorecognition by the host immune system. To examine this issue, we asked whether AChEs PEGylated to different extents differ in their immunogenic potential.
Antigenicity of AChE Is Affected by the Number of Attached PEG Chains-We have previously demonstrated that when administrated repeatedly to mice, nonmodified human AChE elicited high levels of anti-AChE antibodies (11, 22) . It was also noted that repeated administration of randomly PEGylated wild type AChE containing an average of four or five PEG chains resulted in the generation of considerably less antiAChE antibodies (22) , suggesting that PEG appendage results in the conversion of the AChE molecule into an "immunologically inert" form, probably through a masking effect. Because PEGylated Lys 53 /Lys 470 /Lys 496 /Lys 538 AChE and PEGylated Lys 470 AChE, which contain five and two PEG chains, respectively, differed in their ability to interact with the asialoglycoprotein receptor removal system, we decided to examine whether this phenomenon would be also reflected in the differential ability of these two PEG-AChEs to elicit anti-AChE antibodies in animals. These two AChEs in their non-PEGylated and PEGylated forms were repeatedly administered to mice at monthly intervals, and anti-AChE antibody levels were determined 3 weeks following each injection (Fig. 5) . Mice administered with non-PEGylated AChEs displayed, as expected, substantial levels of anti-AChE antibody even after two injections (antibody titers ϭ 1500), and antibody levels increased significantly following a third injection (antibody titers ϭ 9000). In contrast, in mice administrated with the five-PEGylated Lys 53 / Lys 470 /Lys 496 /Lys 538 AChE, anti-AChE antibody levels were consistently low throughout the experiment with barely detectable antibodies after two injections and at least 25-fold lower levels of antibody following the third injection (titers ϭ 320), as compared with non-PEGylated AChE. Determination of antiAChE antibody levels in mice administered with PEGylated Lys 470 AChE, which contains only two PEG chains, demonstrated that this molecular form elicited anti-AChE antibodies, albeit at an intermediate level; Following two injections with PEG-Lys 470 antibody titers were ϳ450, whereas following a third injection titers of 1700 could be determined. These values are lower than those obtained with non-PEGylated AChE, (1500 and 9000 following the second and third injections, respectively) yet are considerably higher than the titers elicited by five-PEGylated AChE (100 and 320 following the second and third injections, respectively). We note that these differences in antibody levels are doubly significant in view of the fact that the five-PEG AChE has a longer interval of antigen presentation than the two-PEG AChE, whereas both PEG-AChEs display longer intervals of antigen presentation than the non-PEGylated form of the enzyme. Taken together, these findings clearly attest to the existence of an inverse correlation between the number of attached PEG chains and the immunogenicity of the human AChE molecule in the mouse heterologous system.
Effect of PEG Localization on the Circulatory Lifetime of AChEs-
The pharmacokinetic profiles of the various PEGylated hypolysine AChEs clearly demonstrate that the number of appended PEG chains plays a pivotal role in determining the circulatory residence time of the enzyme. Yet the finding that low level PEGylation results in the generation of enzyme forms that can still interact with receptor-related clearance mechanisms as well as with the host immune system strongly supports the notion that PEG conjugation operates, at least in part, by concealing surface-related determinants. This potential shielding/masking effect of appended PEG chains may therefore depend to some extent on their actual location on the molecular surface. If so, two PEGylated enzyme forms carrying the same number of PEG chains yet differing in the spatial location of these chains may exhibit differential pharmacokinetic properties.
To examine this issue, we generated and examined hypolysine mutant pairs, which contain equal numbers of PEG chains at different surface locations. We reasoned that the maximal effect of PEG location on circulatory residence will be revealed in enzyme forms that demonstrate intermediate circulatory retention times upon PEGylation, such as dilysine AChE (Fig.  3A) . We therefore generated, based on the three-dimensional model of AChE, an additional dilysine AChE, as well as an additional trilysine AChE. Fig. 6 ).
All seven lysine residues within the three-dimensional model of wild type human ⌬C-rHuAChE are present at the surface of the enzyme, and when this three-dimensional model is rotated around its principal axes (x or y axis), one or more of the eight anchoring points for PEG appendage (seven lysines residues and the N-terminal amine) can be observed on each and every quadrant of the molecular surface (Fig. 6A) , suggesting that ample coverage of the enzyme surface may be attained by appendage of PEG chains to all of the lysine residues. When the three-dimensional models of the various Lys-Ala mutant AChEs are similarly rotated around their principal axes, we could determine that although some display at least a single potential-PEG anchoring point on each and every quadrant of the molecular surface, others exhibit surface quadrants that are devoid of such PEG anchoring points. Specifically, examination of the three-dimensional model of the dilysine-mutated AChE initially chosen for this study, Lys 53 /Lys 538 AChE, demonstrated that this enzyme form exhibits an exposed surface quadrant (Fig. 6B) , suggesting that its PEG target sites may be unevenly distributed. However, unlike the Lys 53 /Lys 538 AChE, the dilysine AChE, chosen based on the three-dimensional model Lys 470 /Lys 538 AChE, exhibits a least one PEG anchor site at each of its surface quadrants (Fig. 6C) . Similarly, the PEG target site distribution of the trilysine AChE, Lys 53 /Lys 332 / Lys 538 AChE demonstrated that this enzyme form exhibits no exposed surface quadrants, whereas the three-dimensional /Lys 47 ) were generated, produced, purified, and subjected to PEGylation (Figs. 1 and 2 ) under conditions that favor PEG saturation and subsequently examined for their pharmacokinetic behavior in mice (Fig. 3B ). In accordance with the hypothesis that PEG target site distribution contributes to circulatory retention, PEG-Lys 470 /Lys 538 AChE, which displays a PEG anchor point on each of its surface quadrants, was retained in the circulation for substantially longer periods of time than its PEGylated dilysine counterpart, Lys 53 /Lys 538 AChE, which exhibits an exposed surface quadrant (MRT values of 1320 and 770 min, respectively; Fig. 3B ). Differences in the residence times observed for the two four-PEG AChEs examined (see Fig. 3B , two right bars) may also be attributed to presence of an exposed surface quadrant in one of these structures (Lys 53 /Lys 348 /Lys 470 AChE); however, we are aware that MRT values in the case of the four-PEG AChEs are close to maximal level and well within the experimental error. In conclusion, we demonstrate that pairs of AChE forms containing the same number of appended PEGs, and thereby exhibiting identical molecular weights (Fig. 2) , may nevertheless reside in the circulation for different spans of time because of the unequal spatial distribution of their PEG chains, consistent with their ability to mask the surface of the enzyme.
DISCUSSION
Random PEG conjugation of recombinant acetylcholinesterase of either bovine or human source leads to the generation of enzyme molecules that reside for long periods of time in the circulation of mice and rhesus macaques (11, 12) . In rhesus macaques, the MRT values of recombinant AChE following PEG conjugation are similar to those exhibited by native cholinesterases, which normally reside in the circulation (MRT PEG-AChE ϭ 9700 min; MRT rhesus-BChE ϭ 9500 min, 11). To further probe the mechanism by which PEG conjugation converts AChE into a circulatory long-lived molecule, we asked the following questions: (i) Can a linear relationship be established between the circulatory residence time values displayed by different PEG-AChEs and their number of appended PEG chains? (ii) Is there an upper threshold where the appendage of more PEG moieties will not lead to an additional extension of the enzyme's circulatory residence? (iii) Does the location of the PEG on the enzyme surface play a role in determining the pharmacokinetic behavior of the modified enzyme? (iv) Can one assess whether PEGylation extends circulatory retention of AChE solely by its effect on the molecular mass of the enzyme or also by shielding the enzyme from receptors involved in clearance? Answers to these questions would also be of relevance to many other biomolecules, for which such analysis may be more difficult, if not impossible, to perform because they do not have a native built-in reporter unit as is the case for the very catalytically efficient AChE molecule.
Previous studies allowed us to establish that no more than four to five PEG chains can be added to ⌬C-rHuAChE without compromising its enzymatic activity (12) . Because the ⌬C-rHuAChE enzyme exhibits, in addition to the N terminus, seven lysine target sites at its surface, all of which are available for PEGylation, the conjugation of PEG chains under conditions that promote appendage of no more than four or five chains/enzyme molecule, will necessarily result in the generation of a widely varied population of chemically modified enzyme products (80 -56 different possible PEG products, respectively). The complexity of the resulting products of random PEGylation is further increased because of the fact that under conditions that promote partial PEGylation (four or five PEGs/enzyme only), molecules carrying lesser amounts of PEG chains (zero to three PEG chains/enzyme) are also generated to varying extents (see, for example, the molecular mass distribution of randomly PEGylated wild type AChE in Fig. 2 , right lane). Needless to say, this complex mixture of PEGylated AChE forms is not amenable to any rigorous analysis aimed to evaluate the role of either PEG number or its location in determining the circulatory performance of the enzyme. We therefore generated in this study an array of specific lysine-to-alanine mutant rHuAChE molecules displaying different yet well defined combinations of a limited number of PEG target sites. To this end, (i) we determined that any of the lysine residues of ⌬C-rHuAChE may be eliminated without compromising enzyme activity or structural integrity (Fig. 1) , and (ii) we tailored the various mutants in a manner that allows appendage of no more than five PEGs/enzyme so that PEGylation of these molecules to completion results in the generation of uniformly modified molecules with a well defined number and location of PEG appendages (Fig. 2) while preserving full enzymatic activity. This array of hypolysine AChEs, which can accommodate one, two, three, four, or five PEG chains, allowed us to elucidate in a precise manner, the role of PEG chain number and PEG location in determining the pharmacokinetic performance of the enzyme.
Pharmacokinetic profiling in mice of the various hypolysine AChE enzyme forms containing zero to four lysine residues allowed us to determine unequivocally that a linear relationship exists between PEG load and the circulatory residence time values of the various hypolysine AChE structures. Thus the rank order of MRT values in the circulation was PEG(ϫ5)-AChE ϭ PEG(ϫ4)-AChE Ͼ PEG(ϫ3)-AChE Ͼ PEG(ϫ2)-AChE Ͼ PEG(ϫ1)-AChE Ͼ PEG(ϫ0)-AChE. The most prominent percentage of increase in circulatory lifetime extension was observed when a single PEG chain was added to the only free amine group located at the N terminus of non-PEGylated AChE (ϳ9-fold increase in MRT; Fig. 3A) . Appendage of addi- tional PEG chains resulted in a more gradual increase in MRT values (1.5-2.5-fold increase; Fig. 3A) . The MRT values of AChE containing four PEG chains was ϳ1800 min, whereas addition of a fifth PEG chain did not significantly increase the circulatory residence time of the enzyme molecule, suggesting that no more than four appended PEG molecules are required for obtaining maximal circulatory retention of the enzyme. These results appear to be consistent with the conclusion that the high number of appended PEGs leads to an increase in the mass and size of the molecule, thereby increasing the longevity of the PEGylated molecule in the circulation, probably by preventing elimination through glomerular filtration. However, the extended circulatory residence may be an outcome of PEGdependent concealment of epitopes, which are involved in elimination of the enzyme from the bloodstream. We note in this context that the addition of a single PEG chain to AChE resulted in a greater than 8-fold increase in its circulatory retention time (from 42 to 365 min; Fig. 3A) , even though the increase in molecular weight following appendage of a single PEG chain is less than 30%. In contrast, increasing the molecular weight of the enzyme by 100% through dimerization of AChE subunits resulted in a less than 2-fold increase of its circulatory lifetime (9) .
In the past, we have determined that the pharmacological properties of AChE are affected by glycan loading, glycan sialylation, and subunit assembly into tetrameric forms (8 -10, 17, 18) . In addition, epitopes involved in species-dependent HuAChE removal were also identified (11) . Thus PEG appendage may indeed convert AChE into a circulatory long-lived molecule, not only by enlarging enzyme size but also by preventing interactions with the enzyme surface epitopes. If indeed this is the case, one may expect that the spatial location of PEG chains will affect circulatory retention of the enzyme. To examine this issue, one needs to generate PEG-AChE molecules of identical molecular weight, yet differing in the degree of distribution of their appended PEG chains. To assess PEG chain distribution on the molecular surfaces of different AChE mutants, we examined the presence/absence of PEG anchor sites at the surface of the various AChEs, while rotating the three-dimensional model of the enzyme around its principal axes at increments of 90° (  Fig. 6) . Examination of the dilysine mutant AChEs by this method allowed us to predict that their corresponding PEG target sites are distributed differently. When Lys 53 /Lys 538 AChE is rotated around its x axis, an exposed surface quadrant devoid of any PEG anchoring point is observed, whereas Lys 470 / Lys 538 AChE exhibits PEG anchoring points on each of its surface quadrants (Fig. 6, compare B and C) 538 AChE is in line with the relatively unequal distribution of its PEG attachment sites, as revealed by inspection of the three-dimensional model of the enzyme, suggesting that the positive effect of PEGylation on circulatory lifetime extension is due at least in part to the masking or sequestration of specific epitopes located at the surface of the AChE molecule by the PEG chains. Taken together, the results presented in this study demonstrate that the location of the appended PEG molecules indeed plays a role in determining the pharmacokinetic performance of PEGylated AChE, presumably by effective concealment of surface-related epitopes of the enzyme. We note in this context that the relatively large increase in MRT following the conjugation of a single PEG chain to AChE (ϳ9-fold increase in MRT, as opposed to 1.5-2.5-fold increase following the appendage of a second, third, and fourth PEG chain; Fig. 3A) , may also be due to the specific site of attachment at the N terminus of the enzyme molecule, which is known to be a highly flexible domain (16) .
The interplay between PEGylation of AChE and enzyme surface coverage is also revealed by the differential clearance of PEG-AChEs differing in level of sialylation (Fig. 4) . Although PEGylated AChEs containing five PEG chains/molecule are equally retained in the circulation for long periods of time regardless of their sialylation status, PEG-AChE molecules carrying two PEG chains at identical locations yet exhibiting different levels of sialic acid capping are cleared from the circulation at different rates (Fig. 4, compare B and C) . It therefore seems that in AChE enzyme forms that carry a suboptimal number of PEG chains, epitopes for elimination can still be accessed by removal mechanisms such as the asialoglycoprotein receptor system. This ineffective shielding by a low number of PEG chains is also apparent when examining the levels of anti-AChE antibodies following administration of PEGylated AChEs. Although AChE carrying five PEG chains barely induced anti-AChE antibodies, the development of such antibodies could clearly be discerned in mice administered repeatedly with AChE containing only two PEG chains. Yet, the anti-AChE antibodies in this case were lower than those observed in mice administered with non-PEGylated AChE (Fig. 5) . Thus, although a low number PEG chain appendage confers a shielding effect to the AChE molecule, high level shielding is attained only following the appendage of a high number of PEG chains.
We have shown in the past that recombinant AChEs can be converted into circulatory long-lived enzyme forms exhibiting mean residence time values that are similar to those of native serum-derived cholinesterases, by the combined optimization of post-translation-related factors (sialic acid occupancy, enzyme tetramerization, and glycan loading) (8, 10) . However, obtaining a homogenous long-lived circulatory scavenger through such a biotechnological/biochemical route may be difficult. Random PEGylation of recombinant AChEs also leads to the generation of a circulatory long-lived enzyme, yet the resulting product is of a heterogeneous nature, comprising a mixture of differently PEGylated molecular forms (12) . This problem, which is inherent to random PEGylation of many protein targets, was dealt with by others, through single site PEGylation of either a newly introduced cysteine residue (see for example Refs. 23 and 24) or by N terminus-specific PEGylation (see for example Refs. 25 and 26) . However, as in the case of 1-PEG addition to alysine AChE (Fig. 3A) , other monoPEGylated proteins displayed at most a 10-fold increase in circulatory residence time as compared with their non-PEGylated counterparts. In the present study we show that multiple PEGylation of AChEs, from which care-fully selected lysine residues were removed, can give rise to uniform molecular forms that reside in the circulation of mice for substantially longer periods of time, up to 50-fold higher than non-PEGylated enzyme.
We further show that an inspection of the spatial location of candidate PEG target sites within the three-dimensional model of the enzyme can provide a useful and adequate tool for the judicious selection of target sites for PEGylation. In principle, this methodology may serve for determination of PEG sites of other globular proteins of interest and especially that of BChE another ChE under development as an organophosphate bioscavenger. Like rAChE, rBChEs are also short-lived molecules in the circulation, unless they are modified posttranslationally or by PEGylation (13, 27) . In the case of rBChE, however, generation of homogenous PEGylated molecules would require some careful considerations. AChE contains substantially fewer lysine target sites for PEG conjugation than the BChE enzyme form (BChE, 37 lysines; fulllength AChE, 10 lysines), and therefore reducing the number of BChE lysines without seriously affecting enzymatic properties might be more challenging. One possibility, for example, would be to engineer rBChE with SH appendage PEG target sites, by replacement of selected residues on the surface with cysteines, yet introduction of multiple cysteine residues may in itself be quite demanding (28) . These considerations, together with the fact that unlike BChE, AChE is highly stereoselective toward the toxic enantiomers of various OP agents (14) , imply that AChE may be a preferred template for the generation of homogenous PEG-ChE OP scavengers for therapeutic purposes.
In conclusion, the studies described here with defined differentially loaded PEG-AChEs and especially with hypolysine AChEs carrying the same number of PEGs demonstrate clearly that circulatory longevity correlates with the extent of concealment of the AChE surface, consistent with the distribution of accessible PEG sites on the three-dimensional structure of the enzyme. This shielding/masking effect by PEG maybe even more important than the increase in size because of PEG attachment. In addition, effective sequestration of AChE from the hepatic asialoglycoprotein receptor clearance system, as well as from the immune system, is directly dependent on the extent of PEG loading. Together, all of these observations suggest that PEG molecules effectively conceal surface domains of biomolecules to which they are attached, to an extent that limit the ability of these surface domains to interact with their cognate receptors.
